XML 35 R22.htm IDEA: XBRL DOCUMENT
v3.21.2

BUSINESS COMBINATION (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2021
Business Combinations [Abstract] |
Schedule of Merger Consideration to be Transferred | The following is the Merger Consideration (as defined in the Merger Agreement) was transferred to effect the Merger:
(in thousands) | Total
Deemed (for accounting purposes only) issuance of Foamix shares to Menlo stockholders | $ | 123,757 |
Deemed (for accounting purposes only) conversion of Menlo equity awards | 7,322 |
Total consideration* | $ | 131,079 |
* This amount reflects total consideration prior to reduction in respect of the CSRs (which had a fair value of $19.6 million as of the Merger Date) that were issued to Foamix shareholders and that reduced the Menlo stockholders’ relative ownership in the combined company. If the effect of the CSRs is included, the total consideration deemed paid by Foamix, as the accounting acquirer, to Menlo stockholders and equity award holders in the Merger would be reduced to approximately $111.4 million, as shown in the purchase price allocation table below.
Schedule of Allocation of the Purchase Price to the Fair Values of Assets Acquired and Liabilities Assumed | The Company completed its analysis of the allocation of the purchase price to the fair values of assets acquired and liabilities assumed as follows:
(in thousands) | March 9, 2020
Cash and cash equivalents | $ | 38,641 |
Investment in marketable securities | 22,703 |
Prepaid expenses and other current assets | 1,581 |
In-process research and development | 49,800 |
Goodwill | 4,545 |
Total assets | 117,270 |
Current liabilities | (5,827) |
Total liabilities | (5,827) |
Purchase price* | $ | 111,443 |
* Reflects reduction in the purchase price deemed paid to Menlo stockholders in the Merger on the assumption that the CSRs, in an aggregate value of $19.6 million, convert into additional shares of the combined company for the Foamix shareholders, thereby resulting in a lower percentage of the combined company’s outstanding shares being owned by Menlo stockholders following the Merger.
Schedule of the Calculation for Goodwill of Merger | The purchase price of the transaction and the excess purchase price over the fair value of the identifiable net assets acquired, are calculated as follows:
(in thousands) | March 9, 2020
Purchase price | $ | 111,443 |
Less: fair value of net assets acquired, including other identifiable intangibles | (106,898) |
Goodwill | $ | 4,545 |
Schedule of In Process Research and Development Assets Acquired Through Business Combination | The IPR&D recognized relates to Menlo’s once-daily oral serlopitant for the treatment of pruritus (itch) associated with PN that has not reached technological feasibility as follows:
(in thousands) |  |
Intangible asset |  | Estimated Fair Value
Acquired indefinite life intangible assets* |  | $ | 49,800 |
Fair value of identified intangible assets |  | $ | 49,800 |
* Represents acquired IPR&D assets which are initially recognized at fair value and are classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. Accordingly, during the research and development period, these assets will not be amortized into earnings; instead these assets will be subject to periodic impairment testing.
Schedule of Pro Forma Information | Actual Menlo results of operations included in the condensed consolidated statement of operation for the three and six months ended June 30, 2020:
(in thousands) | Three months ended June 30, 2020 |  | Six months ended June 30, 2020
| (Unaudited)
Revenues | $ | — |  |  | $ | — |
Loss attributable to Menlo | $ | 7,594 |  |  | $ | 19,637 |
| Three months ended June 30, 2020 |  | Six months ended June 30, 2020
(in thousands, except per share data) | (Unaudited) |  | (Unaudited)
SUPPLEMENTAL PRO FORMA COMBINED RESULTS OF OPERATIONS: |  |  |
Revenues | $ | 11,688 |  |  | $ | 13,438 |
Net loss | $ | 167,441 |  |  | $ | 205,082 |
Loss per share - basic and diluted | $ | 1.21 |  |  | $ | 1.23 |
Adjustments to the supplemental pro forma combined results of operations, included in the above, are as follows: |  |  |
Transaction costs | $ | — |  |  | $ | (14,931) |
Acceleration of stock based compensation | — |  |  | (7,199) |
Total Adjustments | $ | — |  |  | $ | (22,130) |

X
- Definition Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(3) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionProFormaInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_BusinessCombinationsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472 + Details
Name: | us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of consideration to be transferred to effect the Merger. + References No definition available. + Details
Name: | vyne_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock
Namespace Prefix: | vyne_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the calculation of goodwill from the business combination. + References No definition available. + Details
Name: | vyne_ScheduleOfBusinessCombinationGoodwillTableTextBlock
Namespace Prefix: | vyne_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of in-process research and development indefinite lived intangible assets acquired in the merger. + References No definition available. + Details
Name: | vyne_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock
Namespace Prefix: | vyne_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration